Keywords: lilly, affinitac, mark, new, turning, point, antisense
Lilly's Affinitac could mark new turning point in antisense therapy
Article | 22 July 2002
Four years ago, the first antisense drug, Isis Pharmaceuticals'Vitravene (fomivirsen) for HIV-associated cytomegalovirus retinitis, reached the market and promised to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
